Raymond James Financial
TERN

Raymond James Financial’s Terns Pharmaceuticals TERN Stock Holding History

Raymond James Financial’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,226
Closed -$1.3M – 5448
2025
Q4 		$1.3M Buy
+32,226
New +$745K ﹤0.01% 3610

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Raymond James Financial's TERN Position: Q1 2026 in Review

Raymond James Financial sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 32,226 shares — an estimated $1.3M sold.

Raymond James Financial first reported a position in TERN in Q4 2025 and held it in 1 quarter. The position peaked at $1.3M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Raymond James Financial reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 32,226 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.3M.
  • Raymond James Financial first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Raymond James Financial's Terns Pharmaceuticals position peaked at $1.3M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.